KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Share-based Compensation (2016 - 2025)

TherapeuticsMD's Share-based Compensation history spans 15 years, with the latest figure at $51000.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 112.5% year-over-year to $51000.0; the TTM value through Dec 2025 reached $75000.0, down 71.59%, while the annual FY2025 figure was $75000.0, 71.59% down from the prior year.
  • Share-based Compensation reached $51000.0 in Q4 2025 per TXMD's latest filing, up from $1000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.3 million in Q3 2021 to a low of $1000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $1.5 million, with a median of $436000.0 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 143.23% in 2021, then crashed 98.96% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $5.3 million in 2021, then plummeted by 79.25% to $1.1 million in 2022, then plummeted by 89.45% to $116000.0 in 2023, then crashed by 79.31% to $24000.0 in 2024, then surged by 112.5% to $51000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Share-based Compensation are $51000.0 (Q4 2025), $1000.0 (Q2 2025), and $23000.0 (Q1 2025).